

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5907205

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ROY LEVITT	12/30/2019
MARCIA LEVITT	12/30/2019
RECEIVING PARTY DATA	
Name:	ONSPIRA THERAPEUTICS INC.
Street Address:	640 LEE ROAD
Internal Address:	SUITE 110
City:	WAYNE
State/Country:	PENNSYLVANIA
Postal Code:	19087
PROPERTY NUMBERS Total: 11	
Property Type	Number
Patent Number:	8940683
Application Number:	14605545
Application Number:	60878385
Application Number:	60907028
Application Number:	60836760
Patent Number:	8637469
Application Number:	14163720
Application Number:	60878397
Application Number:	60907027
Application Number:	60819703
Application Number:	60812874
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	212-728-8000
Email:	ipdept@willkie.com
Correspondent Name:	KHALIL NOBLES
Address Line 1:	787 SEVENTH AVENUE

PATENT

Address Line 4: NEW YORK, NEW YORK 10019	
ATTORNEY DOCKET NUMBER:	126013.00001
NAME OF SUBMITTER:	KHALIL NOBLES
SIGNATURE:	/Khalil Nobles/
DATE SIGNED:	01/13/2020
Total Attachments: 5 source=Levitt IP Assignment + Copy of Exhibit A#page1.tif source=Levitt IP Assignment + Copy of Exhibit A#page2.tif source=Levitt IP Assignment + Copy of Exhibit A#page3.tif source=Levitt IP Assignment + Copy of Exhibit A#page4.tif source=Levitt IP Assignment + Copy of Exhibit A#page5.tif	

PATENT ASSIGNMENT

December 30, 2019

WHEREAS, the undersigned, Dr. Roy Levitt and Marcia Levitt, each a citizen of the United States, residing at 33 North Shore Drive, Miami Beach, FL 33141 (together, the "Assignors"), are the owners of certain intellectual property relating to the treatment of lung diseases through the use of inhaled Anakinra, including but not limited to Bronchiolitis Obliterans Syndrome and Cystic Fibrosis, among others, for which the Assignors filed certain patent applications, as further described in Exhibit A (the "Levitt IP");

WHEREAS, Onspira Therapeutics, Inc., a Delaware corporation, having a mailing address of 640 Lee Road, Suite 110, Wayne, PA 19087 (the "Assignee"), and the Assignors entered into that certain Exclusive Option Agreement, dated as of April 11, 2017, as amended pursuant to Amendment No. 1 to Exclusive Option Agreement dated as of December 18, 2017, Amendment No. 2 to Exclusive Option Agreement dated as of June 20, 2018, Amendment No. 3 to Exclusive Option Agreement dated as of September 20, 2018, Amendment No. 4 to Exclusive Option Agreement dated May 28, 2019, Amendment No. 5 to Exclusive Option Agreement dated September 20, 2019 and Amendment No. 6 to Exclusive Option Agreement dated December 9, 2019 (collectively, the "Option Agreement"), pursuant to which Assignors granted to Assignee the Option (as defined in the Option Agreement) relating to the purchase of the Levitt IP;

WHEREAS, Assignee desires to acquire the entire right, title and interest in and to the Levitt IP, including the applications for patent and the patents which were or may be granted on or as a result thereof in the United States or in any other country;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby freely acknowledged, and intending to be legally bound, the Assignors have sold, assigned, transferred and set over, and by these presents do hereby sell, assign, transfer and set over, to Assignee, and Assignee accepts, the entire right, title and interest in and to the Levitt IP, and in and to such applications for patent and any and all continuations, divisions, and renewals of and substitutes for such applications, and in, to and under any and all patents that were or may be granted on or as a result thereof in the United States and in all other countries, and any reissue or reissues or extension or extensions of such patents, the same to be held and enjoyed by Assignee, its successors, assigns, nominees or legal representatives, to the full end of the term or terms for which such patents respectively may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by Assignors had this assignment, sale and transfer not been made;

Assignors hereby warrant and covenant that they have full right to convey the entire interest herein assigned, and that they have not executed and will not execute any agreement in conflict herewith, and further covenant and agree that they will each time request is made and without undue delay, execute and deliver all such papers as may be necessary or desirable to perfect the title to the Levitt IP, such applications and such patents in Assignee, its successors, assigns, nominees, or legal representatives, and agree to communicate to Assignee or to its nominee all known facts respecting the Levitt IP, such applications and such patents, to testify in any legal proceedings, to sign all lawful papers, to execute all disclaimers and divisional,

continuing, and reissue applications, to make all rightful oaths, and generally to do everything possible to aid Assignee, its successors, assigns, nominees and legal representatives to obtain and enforce for its own benefit proper patent protection for the Levitt IP in the United States and in all other countries; and


Assignors hereby authorize and request the proper governmental authority in the respective country to issue to Assignee the entire right, title and interest, in and to any and all patents for the Levitt IP as set forth on Exhibit A and any and all patents which may be issued and granted on or as a result of the applications as set forth on Exhibit A, in each case, in accordance with the terms of this Patent Assignment.

[Signature Page Follows]


IN WITNESS WHEREOF, the parties hereto have executed this Patent Assignment as of the day and year first above written.


ASSIGNEE:

ONSPIRA THERAPEUTICS, INC.

By: 
Name: Brian Loric
Title: Chief Executive Officer

ASSIGNORS:


Dr. Roy Levin


Marcia Levitt

[Signature Page to Patent Assignment]

EXHIBIT A

Levitt IP

Title	Marker No.	Country	Sub	C/Sub	Type	Status	Application No.	Filing Date	Patent No.	Issue Date	Expiry Date	Record Owner	Legal/Record Owner
LOCALIZED THERAPY OF LOWER AIRWAYS INFLAMMATORY DISORDERS WITH PRO-INFLAMMATORY CYTOKINE INHIBITORS	067389-0001	Australia	03	01V	Pending		2012010433	20 Aug 07				Dr. Roy Levitt	Dr. Roy & Marisa Levitt
		Australia	03	01V	Granted		2012010447	20 Aug 07	2012010447			Dr. Roy Levitt	Dr. Roy & Marisa Levitt
		Australia	03	01V	Granted		2012010438	20 Aug 07	2012010438	13 Jun 19	10 Aug 27	Dr. Roy Levitt	Dr. Roy & Marisa Levitt
		Australia		PCT	Abandoned		2007040000	10 Aug 07				Dr. Roy Levitt	Dr. Roy & Marisa Levitt
		Canada		PCT	Pending		25500519	20 Aug 07				Dr. Roy Levitt	Dr. Roy & Marisa Levitt
		European Patent Convention	01	01V	Pending		19204693.5	10 Aug 07				Dr. Roy Levitt	Dr. Roy & Marisa Levitt
		European Patent Convention		PCT	Allowed		07099701.3	20 Aug 07	2008080	23 Oct 19	10 Aug 27	Dr. Roy Levitt	Dr. Roy & Marisa Levitt
		Japan		PCT	Abandoned		2009-023003	20 Aug 07				Dr. Roy Levitt	Dr. Roy & Marisa Levitt
		Patent Cooperation Treaty		GRD	Closed		PCT/JP07/12800	20 Aug 07				Dr. Roy Levitt	Dr. Roy & Marisa Levitt
		United States of America		PCT	Granted		11/071507	10 Feb 09	6,940,001	27 Jun 15	22 Mar 30	Dr. Roy Levitt	Dr. Roy & Marisa Levitt
		United States of America	01	02B	Allowed		14/005340	28 Jan 10				Dr. Roy Levitt	Dr. Roy & Marisa Levitt
		United States of America	02	02B	United							Dr. Roy Levitt	Dr. Roy & Marisa Levitt
		United States of America	01	PRD	Closed		60/878335	4 Jan 07			4 Jan 08	Dr. Roy Levitt	Dr. Roy & Marisa Levitt
PREVENTION AND THERAPY WITH PRO-INFLAMMATORY CYTOKINE INHIBITORS		United States of America	02	PRD	Closed		60/907308	16 Mar 07			16 Mar 08	Dr. Roy Levitt	Dr. Roy & Marisa Levitt
		United States of America	08	PRD	Closed		60/838358	20 Aug 06			20 Aug 07	Dr. Roy Levitt	Dr. Roy & Marisa Levitt
	067389-0002	Australia		PCT	Expired		2007020779	11 Jul 07	2007020779	20 Dec 12	11 Jul 17	Dr. Roy Levitt	Dr. Roy & Marisa Levitt
		Canada		PCT	Abandoned		25500561	21 Jul 07				Dr. Roy Levitt	Dr. Roy & Marisa Levitt
		European Patent Convention		PCT	Abandoned		07010019.8	11 Jul 07				Dr. Roy Levitt	Dr. Roy & Marisa Levitt
		European Patent Convention	01	01V	Abandoned		14193049.4	11 Jul 07				Dr. Roy Levitt	Dr. Roy & Marisa Levitt
		Patent Cooperation Treaty		GRD	Closed		PCT/JP07/12764	11 Jul 07				Dr. Roy Levitt	Dr. Roy & Marisa Levitt
		United States of America		PCT	Granted		11/071548	22 Jan 09	6,937,499	28 Jun 14	26 Jun 29	Dr. Roy Levitt	Dr. Roy & Marisa Levitt
		United States of America	01	01V	Abandoned		14/163720	24 Jan 14				Dr. Roy Levitt	Dr. Roy & Marisa Levitt
		United States of America	01	PRD	Closed		60/878337	4 Jan 07			4 Jan 08	Dr. Roy Levitt	Dr. Roy & Marisa Levitt
PREVENTION AND THERAPY		United States of America	02	PRD	Closed		60/907307	16 Mar 07			16 Mar 08	Dr. Roy Levitt	Dr. Roy & Marisa Levitt
		United States of America	08	PRD	Closed		60/819318	11 Jul 06			11 Jul 07	Dr. Roy Levitt	Dr. Roy & Marisa Levitt
	067389-0003	United States of America	08	PRD	Closed		10/011374	12 Jun 08			20 Jun 07	Dr. Roy Levitt	Dr. Roy & Marisa Levitt

Copy of Exhibit A

Title	Matter No.	Country	Sub	C-Sub	Type	Status	Application No.	File Date	Patent No.	Issue Date	Expire Date	Record Owner	Legal/Beneficial Owner
LOCALIZED THERAPY OF LOWER AIRWAYS INFLAMMATORY DISORDERS WITH PROINFLAMMATORY CYTOKINE INHIBITORS	067389-5001	Australia		03	DIV	Pending	2019203630	10-Aug-07				Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		Australia		01	DIV	Granted	2013270447	10-Aug-07	2013270447			Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		Australia		02	DIV	Granted	2017200228	10-Aug-07	2017200228	13-Jun-19	10-Aug-27	Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		Australia			PCT	Abandoned	2007284690	10-Aug-07				Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		Canada			PCT	Pending	2,660,519	10-Aug-07				Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		European Patent Convention		01	DIV	Pending	19204691.0	10-Aug-07				Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		European Patent Convention			PCT	Allowed	07836707.5	10-Aug-07	2068889	23-Oct-19	10-Aug-27	Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		Japan			PCT	Abandoned	2009-523863	10-Aug-07				Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		Patent Cooperation Treaty			ORD	Closed	PCT/US07/17800	10-Aug-07				Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		United States of America			PCT	Granted	12/377,027	10-Feb-09	8,940,683	27-Jan-15	22-Mar-30	Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		United States of America	01		CON	Allowed	14/605,545	26-Jan-15				Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		United States of America	02		CON	Unfiled						Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		United States of America	P1		PRO	Closed	60/878,385	4-Jan-07			4-Jan-08	Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		United States of America	P2		PRO	Closed	60/907,028	16-Mar-07			16-Mar-08	Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		United States of America	PR		PRO	Closed	60/836,760	10-Aug-06			10-Aug-07	Dr. Roy Levitt	Dr. Roy & Marcia Levitt
RHINOSINUSITIS PREVENTION AND THERAPY WITH PROINFLAMMATORY CYTOKINE INHIBITORS	067389-5002	Australia			PCT	Lapsed	2007272970	11-Jul-07	2007272970	20-Dec-12	11-Jul-27	Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		Canada			PCT	Abandoned	2,657,581	11-Jul-07				Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		European Patent Convention			PCT	Abandoned	07810329.8	11-Jul-07				Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		European Patent Convention		01	DIV	Abandoned	14190249.4	11-Jul-07				Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		Patent Cooperation Treaty			ORD	Closed	PCT/US07/15784	11-Jul-07				Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		United States of America			PCT	Granted	12/373,448	12-Jan-09	8,637,469	28-Jan-14	16-Jun-29	Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		United States of America	01		DIV	Abandoned	14/163,720	24-Jan-14				Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		United States of America	P1		PRO	Closed	60/878,397	4-Jan-07			4-Jan-08	Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		United States of America	P2		PRO	Closed	60/907,027	16-Mar-07			16-Mar-08	Dr. Roy Levitt	Dr. Roy & Marcia Levitt
		United States of America	PR		PRO	Closed	60/819,703	11-Jul-06			11-Jul-07	Dr. Roy Levitt	Dr. Roy & Marcia Levitt
RHINOSINUSITIS THERAPY	067389-5003	United States of America		PR	PRO	Closed	60/812,874	12-Jun-06			12-Jun-07	Dr. Roy Levitt	Dr. Roy & Marcia Levitt